Bio-Rad Laboratories vs Insulet
Bio-Rad Laboratories (BIO), health care, and Insulet (PODD), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Insulet is worth $10.1B on the stock market and Bio-Rad Laboratories $9.6B: Insulet is valued at 5% more. Bio-Rad Laboratories trades at 9.5 times earnings and Insulet at 23.7; operating margins in their latest fiscal years were 1.83% and 17.5%. Over the past year Bio-Rad Laboratories's share price has moved +17.1% and Insulet's -56.4%.
Key facts
- Bio-Rad Laboratories market value
- $9.6B
- Insulet market value
- $10.1B
- Bio-Rad Laboratories P/E
- 9.5
- Insulet P/E
- 23.7
- Bio-Rad Laboratories revenue
- $2.6BFY to 2025-12-31
- Insulet revenue
- $2.7BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Bio-Rad Laboratories | Insulet |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $9.6Blower | $10.1Bhigher |
| Revenue | $2.6Blower | $2.7Bhigher |
| Earnings | $759.9Mhigher | $247.1Mlower |
| Employees | 7,450higher | 5,400lower |
| Total assets | $10.6Bhigher | $3.2Blower |
| Valuation | ||
| P/E | 9.5lower | 23.7higher |
| P/S | 3.7higher | 3.7lower |
| P/B | 1.3lower | 6.4higher |
| Dividend yield | 0.00% | 0.00% |
| Profitability | ||
| Operating margin | 1.83%lower | 17.5%higher |
| Balance sheet | ||
| Net assets | $7.5Bhigher | $1.5Blower |
| Total liabilities | $3.1Bhigher | $1.7Blower |
| Total debt | $1.2Bhigher | $949.2Mlower |
| Cash on hand | $529.8Mlower | $716.1Mhigher |
| Price change | ||
| Today | -0.57%lower | +0.03%higher |
| 1 year | +17.1%higher | -56.4%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Bio-Rad Laboratories only (3)
- John Rogers3.1%
- Matthew McLennan1.5%
- Steven Romick1.2%
Insulet only (1)
- Eric Bannasch9.7%
Percentages are each holding's share of that investor's reported portfolio. Who owns BIO · Who owns PODD
More on Bio-Rad Laboratories
Further comparisons
Bio-Rad Laboratories against its closest peers
Insulet against its closest peers
Learn
Questions and answers
Which is bigger, Bio-Rad Laboratories or Insulet?
By market value, Insulet is the larger: $10.1B against $9.6B for Bio-Rad Laboratories. By revenue in its latest fiscal year, Insulet is the larger: $2.7B against $2.6B for Bio-Rad Laboratories.
Which has the higher P/E ratio?
Insulet: 23.7, against 9.5 for Bio-Rad Laboratories. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Insulet: 17.5%, against 1.83% for Bio-Rad Laboratories. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which has the higher dividend yield?
Neither: both stand at 0.00%. Dividend yield is the last twelve months' dividends as a share of today's share price.
Which has more debt?
Bio-Rad Laboratories: $1.2B, against $949.2M for Insulet. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.
Which superinvestors own both Bio-Rad Laboratories and Insulet?
None of the tracked superinvestors holds both in their latest 13F filing. 3 hold Bio-Rad Laboratories and 1 holds Insulet.
Cite this page
Funkfolio, “Bio-Rad Laboratories vs Insulet”, data as of 17 November 2026. https://funkfolio.com/compare/bio-vs-podd
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.